Following the OlympiA trial (NCT02032823) [16], the NCCN also recommend adjuvant treatment with olaparib following chemotherapy in select patients with gBRCA-mutated, HER2-negative BC [14], with further germline testing recommendations to identify patients eligible for PARP inhibitors in the high-risk newly diagnosed and metastatic settings [17]. The gene discussed is ERBB2; the disease is breast cancer.